Brief: Gamida Cell Reports Full Year 2022 Financial Results

Gamida Cell

27/03/2023 15:22

March 27 (Reuters) - Gamida Cell Ltd  GMDA.O :
    * GAMIDA CELL REPORTS FULL YEAR 2022 FINANCIAL RESULTS AND
PROVIDES COMPANY UPDATE
    * GAMIDA CELL - TO EXPLORE STRATEGIC OPTIONS TO SUPPORT
BROADER
LAUNCH OF OMIDUBICEL, INCLUDING POTENTIAL US, GLOBAL
PARTNERSHIPS WITH PHARMACEUTICAL COS
    * GAMIDA CELL - INTENDS TO CONTINUE GDA-201 PHASE 1 STUDY,
DISCONTINUE DEVELOPMENT OF NATURAL KILLER (NK) CELL PRECLINICAL
CANDIDATES
    * GAMIDA CELL LTD - INTENDS TO CONSOLIDATE ITS OPERATIONS IN
ISRAEL IN KIRYAT GAT
    * GAMIDA CELL LTD - CO REPORTS ON PRODUCTIVE INTERACTIONS
WITH FDA
& PREPARATIONS FOR LAUNCH OF OMIDUBICEL, IF APPROVED, IN ADVANCE
OF MAY 1 PDUFA DATE
    * GAMIDA CELL LTD - COMPANY OUTLINES STRATEGIC
RESTRUCTURING,
PLANS TO PRIORITIZE OMIDUBICEL LAUNCH AND REDUCE OPERATING
EXPENSES TO EXTEND CASH RUNWAY
    * GAMIDA CELL LTD - EXPECTS ITS CURRENT CASH AND CASH
EQUIVALENTS
WILL SUPPORT COMPANY'S ONGOING OPERATING ACTIVITIES THROUGH Q3
OF 2023
    * GAMIDA CELL LTD - WILL CONTINUE TO ENROLL PATIENTS IN ITS
GDA-201 PHASE 1 DOSE ESCALATION STUDY
    * GAMIDA CELL LTD - WILL IMPLEMENT A HEADCOUNT REDUCTION OF
17%
    * GAMIDA CELL LTD - MAJORITY OF IMPACTED HEADCOUNT TIED TO
DISCONTINUATION OF PRE-CLINICAL NK CELL THERAPY CANDIDATES
    * GAMIDA CELL LTD - CHANGES ARE EXPECTED TO EXTEND COMPANY'S
CASH
RUNWAY THROUGH Q3 2023

Source text for Eikon:  ID:nBwrgZZWa 
Further company coverage:  GMDA.O